NCT00305734View on ClinicalTrials.gov

Bortezomib and Gemcitabine in Treating Patients With Recurrent or Metastatic Nasopharyngeal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

July 31, 2007

Conditions
Recurrent Nasopharyngeal CancerStage IV Nasopharyngeal Cancer
Interventions
DRUG

bortezomib

Given IV

DRUG

gemcitabine hydrochloride

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

78245

Southwest Oncology Group, San Antonio

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00305734 - Bortezomib and Gemcitabine in Treating Patients With Recurrent or Metastatic Nasopharyngeal Cancer | Biotech Hunter | Biotech Hunter